13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0002011932
Total reported value
$162.1M
$162.1M
59 檔
17.2%
In Q4 2024, Exome Asset Management LLC's U.S. equity holdings reached a combined market value of $162.1M, distributed across 59 disclosed stock positions.
During Q4 2024, Exome Asset Management LLC's portfolio maintained high stability with no major positional turnover, reflecting a continuous long-term holding approach.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | BBIO | Bridgebio Pharma Inc | Stock-Healthcare | 5.09% | -1.75% | +16.92% | |
| 2 | LLY | Eli Lilly & Co | Stock-Healthcare | 4.78% | +0.72% | -21.06% | |
| 3 | GERN | Geron CORP | Stock-Other | 4.22% | +0.49% | NEW | |
| 4 | HUM | Humana Inc | Stock-Healthcare | 3.44% | — | — | |
| 5 | GH | Guardant Health Inc | Stock-Healthcare | 3.39% | +2.30% | +64.59% | |
| 6 | RLAY | Relay Therapeutics Inc | Stock-Other | 3.35% | -0.88% | +161.31% | |
| 7 | IRON | Disc Medicine Inc | Stock-Other | 3.29% | — | +7.06% | |
| 8 | SNDX | Syndax Pharmaceuticals Inc | Stock-Other | 3.17% | — | — | |
| 9 | ARVN | Arvinas Inc | Stock-Other | 3.15% | — | — | |
| 10 | GPCR | Structure Therapeutics Inc | Stock-Other | 3.10% | — | +26.46% | |
| 11 | ISRG | Intuitive Surgical Inc | Stock-Healthcare | 2.91% | -0.32% | — | |
| 12 | APLSUSD | Apellis Pharmaceuticals Inc | Stock-Other | 2.86% | -1.78% | EXIT | |
| 13 | BMY | Bristol-myers Squibb Co | Stock-Healthcare | 2.77% | — | -16.41% | |
| 14 | BSX | Boston Scientific CORP | Stock-Healthcare | 2.72% | -0.30% | — | |
| 15 | NTRA | Natera Inc | Stock-Healthcare | 2.67% | +0.38% | — | |
| 16 | SLNOEUR | Soleno Therapeutics Inc | Stock-Other | 2.61% | -1.07% | EXIT | |
| 17 | SRRK | Scholar Rock Holding CORP | Stock-Other | 2.51% | — | -41.79% | |
| 18 | NUVL | Nuvalent Inc-a | Stock-Other | 2.39% | — | +103.46% | |
| 19 | CYTK | Cytokinetics Inc | Stock-Healthcare | 2.33% | -0.38% | +12.46% | |
| 20 | 2655787D | Blueprint Medicines CORP | Stock-Other | 2.08% | — | -13.35% | |
| 21 | GILD | Gilead Sciences Inc | Stock-Healthcare | 2.06% | — | -40.60% | |
| 22 | SMMT | Summit Therapeutics Inc | Stock-Other | 1.75% | — | — | |
| 23 | 260 | Centessa Pharmaceuticals-adr | Stock-Other | 1.73% | — | -0.32% | |
| 24 | EWTX | Edgewise Therapeutics Inc | Stock-Other | 1.63% | — | +36.02% | |
| 25 | JANX | Janux Therapeutics Inc | Stock-Other | 1.61% | — | — | |
| 26 | SVRA | Savara Inc | Stock-Other | 1.61% | — | — | |
| 27 | IONS | Ionis Pharmaceuticals Inc | Stock-Healthcare | 1.61% | +0.04% | — | |
| 28 | PEN | Penumbra Inc | Stock-Healthcare | 1.61% | +0.16% | — | |
| 29 | RCKT | Rocket Pharmaceuticals Inc | Stock-Other | 1.51% | — | — | |
| 30 | AKRO | Akero Therapeutics Inc | Stock-Other | 1.43% | — | -11.01% | |
| 31 | RDY | Dr. Reddy's Laboratories-adr | Stock-Other | 1.39% | — | +223.69% | |
| 32 | ONC | Beone Medicines Ltd-adr | Stock-Other | 1.39% | — | -34.64% | |
| 33 | ETNBGBP | 89bio Inc | Stock-Other | 1.32% | — | -25.04% | |
| 34 | TARS | Tarsus Pharmaceuticals Inc | Stock-Other | 1.17% | — | -38.21% | |
| 35 | KPTI 3 10-15-25Bond | Karyopharm Therapeutics | Bond | 1.17% | — | — | |
| 36 | PLRX | Pliant Therapeutics Inc | Stock-Other | 1.02% | — | -30.81% | |
| 37 | FULC | Fulcrum Therapeutics Inc | Stock-Other | 1.00% | — | — | |
| 38 | STOK | Stoke Therapeutics Inc | Stock-Other | 0.94% | — | -35.96% | |
| 39 | LEGN | Legend Biotech Corp-adr | Stock-Other | 0.92% | — | -20.00% | |
| 40 | TECX | Tectonic Therapeutic Inc | Stock-Other | 0.90% | — | -28.24% | |
| 41 | ALVO | Alvotech | Stock-Other | 0.90% | — | — | |
| 42 | VYNE | Vyne Therapeutics Inc | Stock-Other | 0.89% | — | — | |
| 43 | ELDN | Eledon Pharmaceuticals Inc | Stock-Other | 0.79% | — | — | |
| 44 | BHVN | Biohaven Ltd. | Stock-Other | 0.79% | — | — | |
| 45 | GOSS | Gossamer Bio Inc | Stock-Other | 0.75% | — | +134.37% | |
| 46 | ACRS | Aclaris Therapeutics Inc | Stock-Other | 0.73% | — | — | |
| 47 | ANNX | Annexon Inc | Stock-Other | 0.56% | — | — | |
| 48 | VERUEUR | Veru Inc | Stock-Other | 0.56% | — | — | |
| 49 | ✓ | Acelyrin Inc | Stock-Other | 0.55% | — | — | |
| 50 | REPL | Replimune Group Inc | Stock-Other | 0.50% | +0.28% | NEW |
According to official SEC Form 13F filings, Exome Asset Management LLC reported a total U.S. public equity portfolio value of $162.1M across 59 disclosed positions in Q4 2024.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including BBIO, LLY, GERN) accounted for 17.2% of total reported equity market value during Q4 2024.
During Q4 2024, Exome Asset Management LLC's top holdings by market value included BBIO (5.1%)、LLY (4.8%)、GERN (4.2%). The largest single position, BBIO, represented 5.1% of total portfolio value.
In Q4 2024, Exome Asset Management LLC made 0 total portfolio adjustments, initiating 0 new buys, adding to 0 positions, trimming 0 holdings, and fully liquidating 0 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.